

DISEASE SPECTRUM OF SARS-CoV-2 INFECTION IN CHILDREN:

- ✓ Children with suspected COVID-19 to be kept together with caregivers where possible- Check for COVID-19 (confirmatory test: RT-PCR/ CBNAAT; positive RAT is acceptable; if negative confirm with RT-PCR).
- ✓ Confirm COVID-19 before determining severity.
- ✓ Some children may present with symptoms of acute abdomen or other GI symptoms or rarely CNS symptoms.

	SYMPTOMS	INVESTIGATIONS
ASYMPTOMATIC	Child detected Positive in RT-PCR /CB-NAAT RAT but without any symptoms. Parents to be briefed on monitoring for any development of symptoms and likelihood of post COVID illness.	No investigations needed.
MILD	 Fever AND/OR Sore throat, rhinorrhea, cough or nasal blockage AND No fast breathing SpO2 ≥ 94% No danger signs 	No investigations needed.
MODERATE	 Fast breathing (age based): ≥60/min for <2 months, ≥ 50/min for 2-11 months, ≥ 40/min for 1-5 years, ≥ 30/min for >5years. OR SpO2 90-94% on Room air AND No Signs of severe disease 	No lab tests required routinely unless indicated by associated comorbid condition. CBC and CRP may be done. Repeat CBC and CRP after 48 hours if indicated.
SEVERE	 Child with any of these: Central Cyanosis SpO2< 90% Increased respiratory efforts (grunting, severe retraction, or chest indrawing) Lethargy and somnolence Shock Altered consciousness. Multi Organ Dysfunction Syndrome (MODS) 	CBC, LFT, RFT, CRP, ABG, Blood culture and Chest X-ray. Repeat after 48 hours, if clinically indicated. For cardiac involvement- ECG, Echocardiography, cardiac biomarkers- Cardiac troponin, CPK-MB, proBNP Coagulation markers: D-dimer, PT and aPTT, Fibrinogen

CLINICAL MANAGEMENT PROTOCOL FOR CHILD WITH COVID-19

MILD	MODERATE	SEVERE (includir	ng critical)
HOME ISOLATION / COVID CARE CENTRE	ADMIT IN DEDICATED COVID FACILITY	ADMIT IN COVID HDU/ PICU	
Supportive care: Rest, adequate hydration and feeding, ORS, monitor vitals.	Supportive care: Adequate hydration and feeding (may need nasogastric feeding), ORS (avoid dehydration and overhydration), monitor vitals.	Supportive care: Maintain (avoid overhydration). Start feeding. Monitor vitals.	adequate hydration early enteral
Symptomatic care: Paracetamol 10-15 mg/kg/dose for fever (minimum 4 hours gap between two doses), Use MDI and spacer if any inhaled medications indicated. Avoid nebulization.	Symptomatic care: Paracetamol 10-15 mg/kg/dose for fever (minimum 4 hours gap between two doses), Children who have wheezing use Salbutamol ± lpratropium MDI +Spacer Avoid Nebulisation Supportive/Specific Therapy	Symptomatic Care Paracetamol 10-15 mg/kg/dose through NG tube or IV for fever; Supportive/Specific Therapy Empiric antimicrobials- only if suspicion of concomitant bacterial infection. Oxygen therapy:	Elective intubation if GCS persistently below 8/ refractory shock ARDS: Conservative fluid management strategy, sedation. Oxygen therapy/ respiratory support: 1. Mild ARDS: HENC/NIV
Parents to report if worsening of symptoms: Persistent fever for ≥ 5 days, recurrence of fever, reduction in oral intake, dehydration or decreased urine output, lethargy, shortness of breath OR SpO2<94%.	 Oral antibiotics- only if suspicion of concomitant bacterial infection. If SpO2<94%, start supplemental oxygen therapy through nasal prongs or face mask. Consider steroids: if there is very rapid progression and when other causes of 	Start with NRBM (10 L/min); if no response, step-up to HFNC with a flow of 0.5 to 2 L/kg/min and FiO2 of 40%- 100% to target SpO2 92 to 96% and then titrate according to response. (Increase flow by 0.5 L/kg above 12 kg). If no response – step up to NIV.SpO2 target > 94% during resuscitation (once	2. Severe ARDS: Mechanical ventilation: Low tidal volume (6 ml/kg), high PEEP, cuffed endotracheal tube. Prone if feasible. If poor response, consider HFOV, ECMO.
If home monitoring/ isolation not possible, admit children with mild illness particularly those with co- morbidities such as chronic lung disease, symptomatic heart disease, chronic kidney disease, neurological disorder, malignancies on chemotherapy, diabetes, morbid obesity, immunodeficiency, or on immunosuppressants due to pre-existing conditions etc.	fever are ruled out, OR If saturation is below 94% on supplemental oxygen therapy beyond 5 days of illness, OR fever persisting beyond 7 days with high inflammatory markers. <u>Watch for progression to</u> <u>severe disease.</u>	stable, target SpO2> 90%). Awake proning in children >8 years. Steroids: Dexamethasone 0.15 mg/kg per dose (max. 6 mg) for 1-2 times a day, 5 days (duration may be extended up to 10 days depending on clinical response) is preferred. [Alternatively, Prednisone (1–2 mg/kg/day per dose, maximum dose 60 mg) or Methylprednisolone (1–2 mg/kg/day IV, maximum dose 60 mg) can be used.]	 Shock/ Myocardial dysfunction Crystalloid bolus 10-20 ml/kg over 30-60 min; to be administered fast if child is hypotensive, while monitoring closely. Avoid/ administer carefully if myocardial dysfunction suspected. Monitor for fluid overload. Early inotrope support- epinephrine first- line tractment

HLH, organ failure.

CHILD WITH MIS-C

Diagnostic Criteria for MIS-C [WHO]:

Children and adolescents 0-19 years of age with fever ≥ 3 days **AND two of these**:

- Rash or bilateral non-purulent conjunctivitis or mucocutaneous inflammation signs (oral, hands or feet).
- ✓ Hypotension or shock.
- ✓ Features of myocardial dysfunction, pericarditis, valvulitis, or coronary abnormalities (including ECHO findings or elevated Troponin/NT-pro BNP),
- ✓ Evidence of coagulopathy (elevated PT, PTT, elevated d-Dimers).
- ✓ Acute gastrointestinal problems (diarrhoea, vomiting, or abdominal pain).

AND

✓ Elevated markers of inflammation such as ESR, C-reactive protein, or procalcitonin.

AND

✓ No other obvious microbial cause of inflammation, including bacterial sepsis, staphylococcal or streptococcal shock syndromes.

AND

✓ Evidence of COVID-19 (RT-PCR, antigen test or serology positive), or likely contact with patients with COVID-19.

MILD (Non-life threatening) MIS-C

Fever and stable vital signs. Absence of shock or organ threatening disease.

IV Methylprednisolone (1-2 mg/kg day) for 3 days followed by course of oral steroids tapered over 2–3-week.

For thromboprophylaxis Aspirin 3 - 5 mg/kg/day; max 75 mg/day (contraindication- platelets <80,000/ μL or active bleeding)

If no improvement or worsening of symptoms

Consider IVIG after ruling out alternative diagnoses.

Tiered investigations to be adopted:

Child with non-critical symptoms: Level 1 and work up for tropical infections \rightarrow add Level 2 tests if high clinical suspicion for MIS-C \rightarrow If, MIS-C not confirmed, managed as per usual protocol and re-evaluate after 1-2 days if symptoms persist.

Child with critical symptoms: stabilize \rightarrow Level 1 and 2 tests and work up for tropical infections.

Common tropical infections include: Malaria, Dengue, Enteric fever, Rickettsial illness (scrub typhus), etc.

Investigations:

Level 1: SARS-CoV-2 PCR and serology and both of the following should be present:

- (1) CRP> 5 mg/L and/or ESR > 40 mm in the first hour.
- (2) At least one of these:
 - ALC < 1000/µL,
 - Platelet < 150,000/µL,
 - Na < 135 mEq/L,
 - Neutrophilia (ANC>7700/µL),
 - Hypoalbuminemia (<3 g/dL)

Level 2: Cardiac (ECG, Echocardiogram, proBNP (>400 pg/mL), elevated Troponin T); **Inflammatory markers** (Procalcitonin, Ferritin (>500 ng/ml), prolonged PT or PTT, D-dimer (>0.55 mg/L), Fibrinogen(>400 mg/dL), high LDH, Triglyceride, Cytokine panel); Blood Smear.

SEVERE MIS-C/ Myocardial/ coronary involvement

Shock, respiratory distress, MOD, cardiac manifestations (myocardial dysfunction/ coronary abnormalities).

IVIG + IVMP

- IVMP (Methylprednisolone 1-2 mg/kg/d) and
- IVIG (2 g/kg within 12-24 hrs; Slower administration may be needed in patients with cardiac failure/ fluid overload)

Antimicrobials- based on clinical judgement and microbiological data if child presents with shock.

If no improvement or worsening of symptoms,

- Consider High dose steroids (Methylprednisolone 10-30 mg/kg/day for 3-5 days, max 1 g / day).
- If unresponsive to above, may consider high dose Infliximab for < 5 years with Kawasaki like illness.
- Consult an expert for further therapy e.g.: Anakinra
- Taper steroids over 2-3 weeks while monitoring inflammatory markers (CRP).

Early vasoactive medication in children with shock/ myocardial dysfunction.

Cautious fluid resuscitation

Antiplatelet and anticoagulation therapy (in patients without active bleeding or significant bleeding risk):

- Aspirin 3 5 mg/kg/day; max 75 mg/day (Indications: KD like features; coronary artery Z score>=2.5; thrombocytosis; contraindication- platelets <80,000/ μL)
- **Enoxaparin** (indications: Coronary aneurysm (Z-score > 10) or Thrombosis or LVEF < 35%) Dosage: 1 mg/kg twice daily SC.